Advertisement

Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Organisation › Details

Immatics (Group)

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. The Company’s transformative product candidates are ? best in class ? Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics’ proprietary and world-leading XPRESIDENT® technology. XPRESIDENT® is the most sensitive, unbiased and high-throughput technology capable of identifying targets in virtually any type of cancer and any HLA type. Together with Immatics’ powerful TCR discovery technology XCEPTOR®, these two platforms allow a full range of cancer therapies to be developed. Immatics’ pipeline includes T-cell therapy programs based on the proprietary ACTolog®, ACTengine®and ACTallo® approaches, which are developed in collaboration through Immatics US with University of Texas MD Anderson Cancer Center and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT), and several bispecific TCR and antibody molecules. Operating from Tuebingen, Munich (Germany) and Houston (Texas), the Company has recognized that novel, better and safer targets are the key to developing future cancer immunotherapies and it is Immatics’ mission to deliver the power of T cells to cancer patients. *

 

Period Start 2000-09-01 splitoff
  Today Immatics Biotechnologies GmbH
  Predecessor University of Tübingen (Eberhard-Karls-Universität)
Products Industry cancer drug
  Industry 2 ACTengine® cell therapy product
Persons Person Singh, Harpreet (Immatics 201907– CEO before CSO + CEO of Immatics US + Co-Founder)
  Person 2 Christ, Arnd (Immatics 202010– CFO before InflaRx + Proteros + MediGene + NovImmune + Probiodrug + Hoechst)
     
Region Region Tübingen
  Country Germany
  Street 15 Paul-Ehrlich-Str.
  City 72076 Tübingen
  Tel +49-7071-5397-0
    Address record changed: 2020-12-12
     
Basic data Employees D: 101 to 500 (2020-12-31)
  Currency EUR
  Annual sales 31,253,000 (revenue, consolidated (2020) 2020-12-31)
  Profit -229,616,000 (2020-12-31)
  Cash 207,530,000 (2020-12-31)
     
    * Document for �About Section�: Immatics Biotechnologies GmbH. (7/8/19). "Press Release: Immatics Appoints Harpreet Singh as Chief Executive Officer". Tübingen & Houston, TX.
     
   
Record changed: 2021-05-27

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Immatics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC E Hand 650x300px




» top